- Eat five times a day: three meals and two small snacks emphasizing lean protein, fresh fruit and vegetables, healthy fat.
- Drink pure, filtered water daily, preferably not from plastic.
- Get label savvy - clean foods contain just a few ingredients.
- Avoid processed and refined foods, especially those that contain white flour, sugar, and bread. Any whole grains should be gluten-free whenever possible.
- Avoid high saturated fat, trans fat, fried, or high sugar foods.
- Consume humanely raised meats and buy local whenever possible.
- Consume healthy fats every day.
- Learn about portion sizes ideal to you, the individual.
- Reduce your carbon footprint by eating seasonal and local produce.
- Slow down, savor, and chew. You will enjoy better taste, promote ideal digestion, and reduce stress in the process.
- Pack clean food for you when you're on the go. Refrigerated bags make this easier to do than ever.
- Experience all of the above with family, friends, and coworkers.
Monday, September 20, 2010
The Clean Eating Approach
Clean Eating refers to consuming food in its most natural state, or as close to it as possible. We live and breathe this philosophy. It is not a diet. It is a lifestyle approach to food and its preparation, leading to an improved life - one meal at a time.
Blood tests for secondary factors for osteoporosis
Routine laboratory tests for osteoporosis evaluation
North American Menopause Society, 2010
| Test | Diagnostic result | Possible secondary cause |
|---|---|---|
| Complete blood cell count | Anemia | Multiple myeloma |
| Serum calcium | Elevated | Hyperparathyroidism |
| Low | Vitamin D deficiency, GI malabsorption |
| Serum phosphate | Elevated | Renal failure |
| Low | Hyperparathyroidism |
| Serum 25-hydroxyvitamin D | Low | Undersupplementation, GI malabsorption, celiac disease |
| Serum albumin | Used to interpret serum calcium, nutritional deficiencies | |
| Serum alkaline phosphatase | Elevated | Vitamin D deficiency, GI malabsorption, hyperparathyroidism, Paget's disease, liver/biliary disease |
| Urinary calcium excretion | Elevated | Renal calcium leak, multiple myeloma, metastatic cancer involving bone, hyperparathyroidism, hyperthyroidism |
| Low | GI malabsorption, inadequate intake of calcium and vitamin D |
| TSH | Low | Hyperthyroidism (causes excess bone turnover) |
| High | Hypothyroidism |
| Serum protein electrophoresis | Monoclonal band | Multiple myeloma |
| Tissue transglutaminase antibody (gluten enteropathy) | Elevated | Predictive of celiac disease |
| Creatinine | Elevated | Renal osteodystrophy, possible contraindication to bisphosphonates |
Supplements via genetic tests misleading: says GAO
Dietary supplements are being fraudulently sold as part of misleading genetic tests, according to the US Government Accountability Office (GAO). In an undercover investigation, GAO purchased a variety of direct-to-consumer genetic tests, which claim to identify which health conditions consumers are at a high risk for. As part of their health package, the marketers of these tests offer ‘personalized’ dietary supplements to help prevent the onset of these conditions.
GAO purchased 10 tests from each of four companies, which ranged in price from $299 to $999. The agency selected five donors to pose as fictitious consumers, and sent two DNA samples from each donor to each company. On reception of the results, which provided risk predictions for 15 diseases, GAO made undercover calls to the companies seeking health advice, and also asked the companies about supplement sales. It then consulted with genetic experts to examine the information collated. On examination of the results, GAO found that different tests yielded different results for the same DNA samples. For example, one fictitious consumer was told that he had below average, average and above average risk for prostate cancer. Other results were found to conflict with actual medical histories. For example, a consumer with an implanted pacemaker for an irregular heartbeat was told that he was at decreased risk for developing this condition.
GAO’s report reveals that companies claimed a consumer’s DNA could be used to create personalized supplements to cure diseases, and often used fraudulent endorsements from high-profile athletes to encourage purchases. One company charged $145 per month for these personalized supplements, which were blends of vitamins and nutrients. Other supplement products were sold with no ingredient lists. Consumers were told that these products could cure diseases such as arthritis and high cholesterol, or prevent conditions such as high blood pressure. GAO has briefed FDA, National Institutes of Health and FTC on its findings, and has also referred all the companies it investigated to FDA and FTC for “appropriate action”
Read the full GAO report.
Steve - these companies need to be reigned in because it does a disservice to alternative health and dietary supplements. Kudos to the GAO for bringing this to the forefront.
Wednesday, September 15, 2010
Fibro sufferers find balance
A 12-week course of low-frequency vibration appears to be safe and feasible for improving dynamic balance in women with fibromyalgia, as reported in Arthritis Care & Research.
Whole-body vibration (WBV) has recently emerged as an intervention that can have positive effects on the neural, muscular, and skeletal systems. A patient stands on a platform that oscillates at a particular frequency and amplitude, causing muscle contractions through stimulation of sensory receptors. Of women aged 41 to 65 years who were randomized either to a control group or to the vibration intervention for 12 weeks, dynamic balance improved by 36% over baseline, whereas no benefit was observed in the control group.
The major limitation is the availability of the device, which can cost $1500 to $3000 for home use. Hopefully, the device will become more popular with physical therapists and other rehabilitation centers.
Whole-body vibration (WBV) has recently emerged as an intervention that can have positive effects on the neural, muscular, and skeletal systems. A patient stands on a platform that oscillates at a particular frequency and amplitude, causing muscle contractions through stimulation of sensory receptors. Of women aged 41 to 65 years who were randomized either to a control group or to the vibration intervention for 12 weeks, dynamic balance improved by 36% over baseline, whereas no benefit was observed in the control group.
The major limitation is the availability of the device, which can cost $1500 to $3000 for home use. Hopefully, the device will become more popular with physical therapists and other rehabilitation centers.
Tuesday, September 14, 2010
Avoid statin-induced myalgia
Correction of hyperlipidemia with statins is often limited by the side-effect of statin-induced myalgias. Vitamin D deficiency is also associated with myalgias that resolve with correction of the vitamin D deficiency. Myalgias associated with statin therapy may also resolve with correction of vitamin D deficiency.
Myalgias resulting from vitamin D deficiency are often misdiagnosed as fibromyalgia. Voluntary muscle has a highly specific nuclear receptor for 1-25 (OH) vitamin D and correction of vitamin D deficiency through its action on this receptor improves muscle strength, physical performance, and myalgias. Statins are commonly associated with myalgias, less commonly with myositis, and rarely with rhabdomyolysis.
The clinical experience of many endocrinologists and cardiologists is that the myalgias associated with statin therapy can often be resolved by correcting vitamin D deficiency and supplementing with Co-Enzyme Q10. To date there have been reports of correction of muscle weakness and myopathy with resolution of vitamin D deficiency and associations of vitamin D deficiency and myalgias in statin-treated patients who were studied retrospectively. Southern Medical Journal, September 2010
Myalgias resulting from vitamin D deficiency are often misdiagnosed as fibromyalgia. Voluntary muscle has a highly specific nuclear receptor for 1-25 (OH) vitamin D and correction of vitamin D deficiency through its action on this receptor improves muscle strength, physical performance, and myalgias. Statins are commonly associated with myalgias, less commonly with myositis, and rarely with rhabdomyolysis.
The clinical experience of many endocrinologists and cardiologists is that the myalgias associated with statin therapy can often be resolved by correcting vitamin D deficiency and supplementing with Co-Enzyme Q10. To date there have been reports of correction of muscle weakness and myopathy with resolution of vitamin D deficiency and associations of vitamin D deficiency and myalgias in statin-treated patients who were studied retrospectively. Southern Medical Journal, September 2010
Frugal Tips for Food Intolerant Shoppers
Food allergies affect more than 12 million Americans and many millions more have food intolerances, yet safe-food selections are still limited and prices can be double those of "normal" foods. Dealing with celiac disease, food allergies (primarily dairy, egg, soy, wheat, peanut, tree-nut, fish and shellfish), and food intolerances are enough of a challenge without the extra expense and time investment required.
Tips for how to manage the extra costs:
Tips for how to manage the extra costs:
- Meal Planning
Reducing food costs begins with a recommendation to plan ahead. Cooking with allergy-safe foods, however, requires even more planning. Until you've developed a solid repertoire of safe recipes and products, it's easy to overspend. Our food consultant Carolyn Martinelli, can help you with this. - Read Labels Carefully
Check labels carefully to make sure you're not buying unsafe products that end up in the garbage can. It's a great help that FDA regulations require manufacturers list the top eight food allergens in plain language, either in the body of the ingredients or in boldface after the ingredients. Be aware, however, that some foods may include hidden allergens. In particular, check prepared foods (anything made from more than one ingredient) for a warning that the food was made in a factory where your allergens may have been used on the same manufacturing lines. - Strike-Point Shopping
Strike-point shopping refers to buying large quantities of non-perishables when they're on sale. Unfortunately, specialty allergy foods rarely go on sale, so keep a sharp eye out and stock up when you find sales. - Coupons
Online coupons are one of your best money-saving resources, no matter what your diet. An excellent resource is Mambo Sprouts (http://www.mambosprouts.com/), which provides consumers with natural foods coupon booklets. Some merchants and manufacturers offer coupons and samples on their websites and others will send them to loyal customers who email them directly. You'll also find online coupons at some organic manufacturers, such as Organic Valley (http://www.organicvalley.coop/coupons/). The offerings may be limited but they do offer coupons for wheat-free and non-lactose products. - Buy in Bulk
The easiest way to buy allergy-free foods in bulk is to special order through your favorite stores. Ask the manager or customer service for assistance. - Buy Online
Online grocers like Allergy Grocer (http://allergygrocer.com/) offer loyalty programs with special discounts. Amazon.com sells allergy-safe products (primarily snacks) and periodically offers grocery deals. Remember to figure in shipping costs when ordering online. - Ethnic Stores
Different national food traditions rely on allergy-safe grains and plants less common in American cooking. While you should never buy a product with a label you can't read, some ethnic stores offer excellent prices on allergy-safe grains, fruits and vegetables.
Wednesday, September 8, 2010
Wyeth's Ghostwriting Campaign Appalling
Courtesy of New York Times
Documents unsealed as part of a lawsuit against drug giant Wyeth Pharmaceuticals reveal that the company used ghostwriters to prepare at least 40 medical journal articles promoting the use of its hormone-replacement drug Prempro.
Hormone replacement therapy drugs such as Premarin and Prempro were widely popular in the 1990s among women seeking to avoid the symptoms of menopause. The drugs became some of Wyeth's best sellers, raking in more than $2 billion for the company until a 2002 study showed that they significantly increased women's risk of invasive breast cancer, heart disease and stroke. Later research also implicated the drugs in an increase dementia risk among the elderly.
Use of hormone replacement therapy plummeted, with a corresponding drop in breast cancer rates. Since then, approximately 8,400 lawsuits have been filed against drugmakers Wyeth and Pfizer by more than 10,000 women affected by side effects. More than 8,000 of these lawsuits have been consolidated into a single case, before U.S. District Judge William Wilson in Arkansas.
Wilson ordered Wyeth's ghostwriting documents unsealed in response to a request by the defendants, the journal PLoS Medicine and the New York Times. The documents reveal that between 1997 and 2005, Wyeth paid medical communications firms to ghostwrite at least 40 articles that promoted hormone replacement for treatment of not just menopause symptoms, but also other conditions such as Parkinson's disease. These articles, many of them reviews of prior studies, played up the benefits of the hormone drugs while downplaying their risks. The communications firms also secured doctors to put their names on the studies as authors.
The articles were published in 18 different medical journals. Neither Wyeth nor the studies' purported authors informed the journals that the company had funded the studies and employed their writers.
The case of DesignWrite Inc. is indicative of Wyeth's larger ghostwriting practices. Wyeth hired the firm in 1997, at which time DesignWrite proposed a two-year plan to promote the company's hormone drugs by securing the publication of 30 different articles.
In 2003, the company drafted a 14-page outline of one article, with the author listed as "to be determined." This outline was sent to Dr. Gloria Bachman of the Robert Wood Johnson Medical School in July, and she agreed to put her name on the study. She was sent a draft of the completed article in September and replied, "I had only one correction which I highlighted in red."
The article, which was published in The Journal of Reproductive Medicine in 2005, disparaged non-hormonal treatment for hot flashes, referring to hormone replacement therapy as the "gold standard."
Wyeth paid DesignWrite $25,000 for the production of the article.
The Prempro case is not Wyeth's first ghostwriting scandal; the company was previously forced to pay $21 billion in lawsuits over the diet drug fen-phen, which was also marketed using ghostwriters. Indeed, the new documents suggest that ghostwriting journal articles is a standard practice for many pharmaceutical companies, raising concerns that doctors might have their prescribing habits influenced by articles that were actually produced as part of corporate marketing campaigns.
"The filter is missing when the reader does not know that the germ of an article came from the manufacturer," said attorney James Szaller, representing many of the plaintiffs.
Medical journal publisher Elsevier has announced an investigation into ghostwriting practices, and some journals have started requiring full disclosure of each author's role in producing a paper, as well as any conflicts of interest. Many journals, however, do not require this disclosure, and the extent of ghostwriting practices remains unknown.
"It's almost like steroids and baseball," said Joseph S. Ross, of Mount Sinai School of Medicine. "You don't know who was using and who wasn't; you don't know which articles are tainted and which aren't."
Documents unsealed as part of a lawsuit against drug giant Wyeth Pharmaceuticals reveal that the company used ghostwriters to prepare at least 40 medical journal articles promoting the use of its hormone-replacement drug Prempro.
Hormone replacement therapy drugs such as Premarin and Prempro were widely popular in the 1990s among women seeking to avoid the symptoms of menopause. The drugs became some of Wyeth's best sellers, raking in more than $2 billion for the company until a 2002 study showed that they significantly increased women's risk of invasive breast cancer, heart disease and stroke. Later research also implicated the drugs in an increase dementia risk among the elderly.
Use of hormone replacement therapy plummeted, with a corresponding drop in breast cancer rates. Since then, approximately 8,400 lawsuits have been filed against drugmakers Wyeth and Pfizer by more than 10,000 women affected by side effects. More than 8,000 of these lawsuits have been consolidated into a single case, before U.S. District Judge William Wilson in Arkansas.
Wilson ordered Wyeth's ghostwriting documents unsealed in response to a request by the defendants, the journal PLoS Medicine and the New York Times. The documents reveal that between 1997 and 2005, Wyeth paid medical communications firms to ghostwrite at least 40 articles that promoted hormone replacement for treatment of not just menopause symptoms, but also other conditions such as Parkinson's disease. These articles, many of them reviews of prior studies, played up the benefits of the hormone drugs while downplaying their risks. The communications firms also secured doctors to put their names on the studies as authors.
The articles were published in 18 different medical journals. Neither Wyeth nor the studies' purported authors informed the journals that the company had funded the studies and employed their writers.
The case of DesignWrite Inc. is indicative of Wyeth's larger ghostwriting practices. Wyeth hired the firm in 1997, at which time DesignWrite proposed a two-year plan to promote the company's hormone drugs by securing the publication of 30 different articles.
In 2003, the company drafted a 14-page outline of one article, with the author listed as "to be determined." This outline was sent to Dr. Gloria Bachman of the Robert Wood Johnson Medical School in July, and she agreed to put her name on the study. She was sent a draft of the completed article in September and replied, "I had only one correction which I highlighted in red."
The article, which was published in The Journal of Reproductive Medicine in 2005, disparaged non-hormonal treatment for hot flashes, referring to hormone replacement therapy as the "gold standard."
Wyeth paid DesignWrite $25,000 for the production of the article.
The Prempro case is not Wyeth's first ghostwriting scandal; the company was previously forced to pay $21 billion in lawsuits over the diet drug fen-phen, which was also marketed using ghostwriters. Indeed, the new documents suggest that ghostwriting journal articles is a standard practice for many pharmaceutical companies, raising concerns that doctors might have their prescribing habits influenced by articles that were actually produced as part of corporate marketing campaigns.
"The filter is missing when the reader does not know that the germ of an article came from the manufacturer," said attorney James Szaller, representing many of the plaintiffs.
Medical journal publisher Elsevier has announced an investigation into ghostwriting practices, and some journals have started requiring full disclosure of each author's role in producing a paper, as well as any conflicts of interest. Many journals, however, do not require this disclosure, and the extent of ghostwriting practices remains unknown.
"It's almost like steroids and baseball," said Joseph S. Ross, of Mount Sinai School of Medicine. "You don't know who was using and who wasn't; you don't know which articles are tainted and which aren't."
